Clinical phase III comparative study on garenoxacin versus levofloxacin in patients with bacterial pneumonia

DOI 2 Citations 11 References
  • Kobayashi Hiroyuki
    Kyorin University School of Medicine
  • Watanabe Akira
    Department of Respiratory Medicine, Division of Cancer Control, Institute of Development, Aging and Cancer, Tohoku University
  • Aoki Nobuki
    Department of Internal Medicine, Shinrakuen Hospital
  • Odagiri Shigeki
    Odagiri Respiratory Disease Clinic
  • Kawai Shin
    First Department of Internal Medicine, Kyorin University School of Medicine
  • Niki Yoshihito
    Division of Respiratory Diseases, Department of Internal Medicine, Kawasaki Medical School
  • Kohno Shigeru
    Second Department of Internal Medicine, Nagasaki University
  • Saito Atsushi
    First Department of Internal Medicine, School of Medicine, University of Ryukyus

Bibliographic Information

Other Title
  • 細菌性肺炎を対象としたgarenoxacinの臨床第III相比較試験

Search this article

Description

The clinical efficacy and safety of garenoxacin mesilate hydrate (GRNX), a novel des-fluoro quinolone, and levofloxacin (LVFX) for bacterial pneumonia were investigated double blind. Clinical efficacy was observed at the end day of treatment, and comparing the results of the 7th day after treatment completion in European and South American studies, patients were treated with either GRNX 400 mg once daily (GRNX group) or LVFX 100 mg three times daily (LVFX group) for 10 days.<BR>The efficacy rates at the end day of treatment were 99.1%(111/112) in the GRNXgroup and 94.9%(82/87) in the LVFX group. The noninferiority of GRNX against LVFX was demonstrated. Theefficacy rates at the 7th day after treatment completion were 94.9%(94/99) in the GRNX group and 92.8%(77/83) in the LVFX group. Bacteriological efficacy was 100% in both the GRNX group (59/59) and the LVFX group (40/40). The bacteriological eradication rates at the 7th day after treatment completion were100%(50/50) in the GRNX group and 86.8%(33/38) in the LVFX group. The incidence of drug-induced adverseevents, including laboratory abnormalities was 35.6%(48/135) in the GRNX group and 27.1%(32/118) in the LVFX group, indicating no significant difference between groups. The sort and grade of adverse events were also similar between groups, and no strange event was observed.<BR>The efficacy rate of GRNX at the 7th day after treatment completion was 89.9%(89/99) in European and South American studies. The clinical efficacy and safety which were observed in our study were similar to those of overseas results.<BR>Summarizing this study, GRNX, a 400 mg oral dose once daily for 10 days, shouldbe clinically a very useful medication in the treatment of bacterial pneumonia.

Journal

Citations (2)*help

See more

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top